ITOS
Price:
$10.15
Market Cap:
$448.68M
iTeos Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the discovery and advancement of immuno-oncology therapies for patients. The company's pipeline includes two principal investigational drugs: inupadenant, a small molecule designed as an antagonist of adenosine A2AR, which is currently undergoing Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT (T-cell immunoreceptor with Ig and ITIM domains), presently in Phase 1/2 clinical assessment. Furthermore, EOS-448's mechanism involves engaging the Fc gamma receptor (FcγR) to activate dendritic cells and macrophages, thereby promoting antibody-dependent cellular cytotoxicity (ADCC). Established...[Read more]
Industry
Biotechnology
IPO Date
2020-07-24
Stock Exchange
NASDAQ
Ticker
ITOS
According to iTeos Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -2.15. This represents a change of 15.23% compared to the average of -1.86 of the last 4 quarters.
The mean historical PE Ratio of iTeos Therapeutics, Inc. over the last ten years is -5.50. The current -2.15 PE Ratio has changed 3.81% with respect to the historical average. Over the past ten years (40 quarters), ITOS's PE Ratio was at its highest in in the September 2022 quarter at 180.96. The PE Ratio was at its lowest in in the March 2020 quarter at -28.82.
Average
-5.50
Median
-3.48
Minimum
-31.16
Maximum
7.64
Discovering the peaks and valleys of iTeos Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 270.55%
Maximum Annual PE Ratio = 7.64
Minimum Annual Increase = -148.39%
Minimum Annual PE Ratio = -31.16
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | -2.31 | -33.48% |
| 2023 | -3.48 | -148.39% |
| 2022 | 7.18 | -5.92% |
| 2021 | 7.64 | -124.50% |
| 2020 | -31.16 | 270.55% |
| 2019 | -8.41 | 6.13% |
The current PE Ratio of iTeos Therapeutics, Inc. (ITOS) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
0.46
5-year avg
-4.43
10-year avg
-5.50
iTeos Therapeutics, Inc.’s PE Ratio is greater than Invivyd, Inc. (-3.07), greater than Sinovac Biotech Ltd. (-6.45), less than Revance Therapeutics, Inc. (-0.95), less than Checkpoint Therapeutics, Inc. (-0.06), greater than Sage Therapeutics, Inc. (-2.62), greater than Climb Bio, Inc. (-14.78), greater than Vigil Neuroscience, Inc. (-5.26), greater than Orchard Therapeutics plc (-27.11), greater than Big Cypress Acquisition Corp. (-1134.54), greater than G1 Therapeutics, Inc. (-7.72),
| Company | PE Ratio | Market cap |
|---|---|---|
| -3.07 | $102.20M | |
| -6.45 | $464.94M | |
| -0.95 | $381.02M | |
| -0.06 | $367.72M | |
| -2.62 | $544.94M | |
| -14.78 | $780.03M | |
| -5.26 | $375.71M | |
| -27.11 | $380.11M | |
| -1134.54 | $425.36M | |
| -7.72 | $377.75M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like iTeos Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like iTeos Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is iTeos Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for iTeos Therapeutics, Inc. (ITOS)?
What is the highest PE Ratio for iTeos Therapeutics, Inc. (ITOS)?
What is the 3-year average PE Ratio for iTeos Therapeutics, Inc. (ITOS)?
What is the 5-year average PE Ratio for iTeos Therapeutics, Inc. (ITOS)?
How does the current PE Ratio for iTeos Therapeutics, Inc. (ITOS) compare to its historical average?